|
Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality
Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers, one of the largest ketamine clinics in the country.
Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses. Its founders helped build the multi-billion-dollar cannabis industry and aim to do the same in psychedelics as it follows a similar path toward legalization. In its quest to advance the
new psychedelic renaissance upon us, Delic has become the pioneer in its field, creating an ecosystem of opportunities by investing in cutting-edge ideas.
The Vancouver-based company was formed in 2019 to address the growing interest in psychedelic wellness backed by science. Delic was the first psychedelic umbrella platform. It is currently a trusted source for those interested in psychedelic culture, education, treatments, and more.
While other emerging companies focus on patent medicine and big pharma for substances limited by government regulation, Delic is blazing a unique trail. It identifies ancillary and fully legal opportunities like IP, new media, live events, ketamine clinics (with the ability to offer additional psychedelic treatments once legalized, and large-scale production and brings them
under its big tent of resources and reach.
Investment Considerations
- Delic is led by a best-in-class team of industry veterans with over 100 years of working knowledge in cannabis, finance, and psychedelic research.
- The Vancouver-based company was formed in 2019 as the first psychedelic umbrella platform.
- The Delic self-sustaining Ecosystem covers three main areas: media, health, and science.
- On March 4, 2021, Delic announced its acquisition of Seattle-based Homestead Book Company, a legacy counterculture distributor of psychedelic media.
- An estimated $238 billion is spent annually in the U.S. on mental health treatments and ancillary services.
- University-led and FDA-approved studies are positioning North America as a leading region in the advancement of psychedelics for therapeutic, medical, and recreational use.
Additional Resources
|
|
RECENT COVERAGE
PsychedelicNewsBreaks - Delic Holdings Corp.'s (CSE: DELC) (OTCQB: DELCF) Ketamine Clinics Improving Accessibility and Reach, Helping Greatest Number of Patients
February 25, 2022 12:00 PM
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is working to make psychedelic-based treatments more accessible and affordable by leveraging its growing chain of clinics in the United States. In 2021, Delic completed the acquisitions of Ketamine Infusion Centers (“KIC”) and Ketamine Wellness Centers
(“KWC”). These acquisitions brought the number of operational wellness clinics under the Delic umbrella to 12. “According to Delic, these clinics are strategically located in secondary cities to improve accessibility and reach as well as help the greatest number of patients. Still, the company plans to serve even more people with the opening of 14 additional clinics over the next 18 months as well as expansion into localities where access to mental health treatments is
limited,” a recent article reads. Delic co-founder and CEO Matt Stang comments: “At Delic, we have built the most profitable model for scaling the best-in-class care directly to patients through the largest network of mental health clinics in the U.S. We see a strong outlook for Delic with the rollout of 14 additional clinics and an expansion into communities where access to these life-changing treatments is very limited.”
|
